The introduction of innovative product pipelines by Nigerian pharmaceutical companies across a wide spectrum, huge market investment and the surge in non-communicable diseases (NCDs) such as diabetes, hypertension and cancer have helped to shoot up Nigerian drug-makers’ revenues, according to Busi
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
BusinessDay
Nigeria's leading finance and market intelligence news report. Also home to expert opinion and commentary on politics, sports, lifestyle, and more
